✦ LIBER ✦

A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B

✍ Scribed by A. Takeda; J. Jones; J. Shepherd; P. Davidson; A. Price

Book ID: 108885961
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 495 KB
Volume: 14
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2006.00808.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Systematic review: treatment of chronic

Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon

✍ A. Y. HUI; H. L.-Y. CHAN; A. Y.-K. CHEUNG; G. COOKSLEY; J. J.-Y. SUNG 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

The safety of pegylated interferon alpha

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

✍ M. van Zonneveld; H. J. Flink; E. Verhey; H. Senturk; S. Zeuzem; U. S. Akarca; Y 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Long-term efficacy and safety of adefovi

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B

✍ Patrick Marcellin; Ting-Tsung Chang; Seng G. Lee Lim; William Sievert; Myron Ton 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 1 views

Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo. The long-term efficacy and safety of AD

48 weeks pegylated interferon alpha-2a i

48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection

✍ C.-K. HUI; L. S. W. LAI; P. LAM; H.-Y. ZHANG; T.-T. FUNG; S.-T. LAI; W.-M. WONG; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Cost-effectiveness analysis of lamivudin

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B

✍ M. BUTI; M. A. CASADO; J. L. CALLEJA; J. SALMERÓN; J. AGUILAR; M. RUEDA; R. ESTE 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

Pegylated α-interferon-2a plus ribavirin

Pegylated α-interferon-2a plus ribavirin compared with pegylated α-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non-randomized study

✍ Amparo Escudero; Felicidad Rodríguez; Miguel A Serra; Juan A Del Olmo; Francisco 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB